Drugs / OVATODIOLIDE
OVATODIOLIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04220411 | Dec 2020 → Dec 2021 | atopic eczema | Arjil Pharmaceuticals LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OVATODIOLIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650359 ↗ |
| Known as | AR-100 (OV) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650359 ↗ |
| Known as | AR100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650359 ↗ |
| Known as | AR100DP1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04220411 ↗ |
| Known as | NSC-156130 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650359 ↗ |
| Known as | NSC-272353 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650359 ↗ |
| Modality | Small molecule | — CHEMBL4650359 ↗ |
| Route | Topical | “The administration of AR100DP1 should be topically applied twice daily on target lesion area(s)” NCT04220411 ↗ |